Nasus Pharma Ltd Net Income (Loss) Available to Common Stockholders, Diluted
Nasus Pharma Ltd (NSRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $5.86 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-03-25
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|
| 2025-12-31 | $5.86M 20-F · filed 2026-03-25 | |
| 2025-06-30 | -$1.25M 6-K · filed 2025-12-29 | |
| 2024-12-31 | $1.53M 20-F · filed 2026-03-25 | |
| 2024-06-30 | -$871.00K 6-K · filed 2025-12-29 | |
| 2023-12-31 | $1.41M 20-F · filed 2026-03-25 |